Supplementary Tables. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis

Supplementary Table 1. Inflation adjustment based on calendar year averages.Supplementary Table 2. Nominal cost outcomes up to 3-year follow-up (LS-means and p-value were adjusted for all baseline comorbidities)Supplementary Table 3. Nominal cost outcomes up to 3-year follow-up among HSCT groupsSupplementary Table 4. Additional patient baseline characteristics overall and by treatment categorySupplementary Table 5. Baseline characteristics for ESA and AZA patients who had transfusion within the first year of follow-upSupplementary Table 6. Median cost (USD) for each treatment group over 3-years and stratified by follow-up monthSupplementary Table 7. Baseline characteristics for patients with incremental TDSupplementary Table 8. Health care resource utilization stratified by follow-up month